ReviewCureus2025
Clinical Effectiveness and Safety of Electrochemotherapy (ECT) in the Treatment of Locally Advanced Melanoma: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advancing Electrochemotherapy in Melanoma and Non-Melanoma Skin Cancer: From Clinical Practice to Emerging Frontiers.International journal of molecular sciences · 2026Review
- The Evolving Role of Intralesional Therapy in In-Transit Melanoma.Current oncology (Toronto, Ont.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Electrochemotherapy (ECT) is a locoregional cancer treatment primarily used in the palliative management of cutaneous metastases from malignant melanoma. However, its clinical effectiveness, safety, and cost-effectiveness in this setting are poorly defined. The aim of this systematic review is to assess the clinical effectiveness, safety, quality of life (QoL) outcomes, and cost-effectiveness of ECT in the treatment of locally advanced stage III/IV melanoma with in-transit metastasis or loco-regional recurrence. A literature search of MEDLINE and Embase from 2005 to 2024 was performed using the keywords "electrochemotherapy" and "skin cancer". After duplicate removal, 708 studies were identified, 107 English-language papers from 2020 to 2024 were screened, with 47 full texts reviewed. Ten studies met the inclusion criteria and were included for review. Data extraction and reporting adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Guidelines. ECT achieved complete response (CR) rates of 24-85.7%, overall response rates (ORRs) of 63-100%, and one-year overall survival of 60.4-92.6%. ECT was well tolerated with minimal systemic toxicity and minor adverse effects. QoL was maintained post-treatment, and cost-effectiveness analysis suggested economic viability in particular patient cohorts. ECT demonstrated improved tumour control and survival outcomes when combined with systemic immunotherapy. ECT is a safe, well-tolerated, and clinically effective treatment for stage III/IV metastatic melanoma, providing a valuable alternative for patients unsuitable for surgery or systemic chemotherapy. Further prospective RCTs are needed to establish its long-term role in melanoma care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.